Premium
Evaluation of treatment and outcomes for Hispanic patients with gastric cancer at Commission on Cancer‐accredited centers in the United States
Author(s) -
Zhao Beiqun,
Leichman Lawrence P.,
Horgan Santiago,
Bouvet Michael,
Kelly Kaitlyn J.
Publication year - 2019
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25408
Subject(s) - medicine , cancer , population , referral , family medicine , environmental health
Background and Objectives Gastric cancer in the Hispanic population commonly presents with poor clinical features. Characteristics of this vulnerable population and optimal therapy for these patients have not been clearly defined. Methods Using the National Cancer Database (2004‐2014), we analyzed patient demographics, clinical factors, treatment‐related factors, and outcomes for Hispanic and non‐Hispanic patients with gastric adenocarcinoma in the United States. Results A total of 129 666 patients were included in this analysis. Hispanics were younger, more often female, had larger tumors, and were more likely to present with metastatic disease (all P < 0.001). Hispanics were more likely to undergo staging laparoscopy (5.6% vs 4.9%; P = 0.037), gastrectomy (63.5% vs 56.9%; P < 0.001), and ≥ 15 lymph nodes examined (56.1% vs 50.5%; P < 0.001). Hispanics were less likely to have negative margins (91.2% vs 92.8%; P = 0.004). Hispanics with stage II/III disease were less likely to receive neoadjuvant therapy (31.7% vs 38.7%; P < 0.001), but more likely to receive multimodal therapy (48.9% vs 46.1%; P = 0.01). Predictors for improved overall survival in Hispanics included multimodal therapy, negative margins, and treatment at an academic center. Conclusions Efforts to optimize treatment of this distinct and growing population of gastric cancer patients should focus on earlier diagnosis, referral to academic centers, and high‐quality surgery.